Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03368729
What this trial is testing

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 Positive Breast Carcinoma
University of Alabama at Birmingham 46
Large-scale testing (Phase 3)Looking for participantsNCT07762885
What this trial is testing

Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery

Who this might be right for
Ductal Carcinoma In Situ, DCIS
Fudan University 636
Early research (Phase 1)Active Not RecruitingNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Testing effectiveness (Phase 2)Looking for participantsNCT05672524
What this trial is testing

Tucatinib and Trastuzumab in People With Rectal Cancer

Who this might be right for
Adenocarcinoma of the RectumLocally Advanced Rectal AdenocarcinomaRectal Adenocarcinoma+2 more
Memorial Sloan Kettering Cancer Center 37
Early research (Phase 1)Ended earlyNCT04209465
What this trial is testing

BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Who this might be right for
Solid Tumor
Black Diamond Therapeutics, Inc. 91
Testing effectiveness (Phase 2)Study completedNCT02614794
What this trial is testing

Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen Inc. 612
Testing effectiveness (Phase 2)Ended earlyNCT04249622
What this trial is testing

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+18 more
Mayo Clinic 20
Early research (Phase 1)Ended earlyNCT03294694
What this trial is testing

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Who this might be right for
Metastatic Hormone-Receptor-Positive (HR+) Breast CancerHER2-Negative Breast CancerMetastatic Epithelial Ovarian Cancer
Dana-Farber Cancer Institute 33
Testing effectiveness (Phase 2)Study completedNCT01730833
What this trial is testing

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

Who this might be right for
HER2-positive Breast CancerRecurrent Breast CancerStage IIA Breast Cancer+7 more
City of Hope Medical Center 63
Testing effectiveness (Phase 2)Looking for participantsNCT07222215
What this trial is testing

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Who this might be right for
Estrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more
Kristina A. Fanucci 297
Testing effectiveness (Phase 2)Ended earlyNCT02457910
What this trial is testing

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
Vanderbilt-Ingram Cancer Center 30
Large-scale testing (Phase 3)Looking for participantsNCT06058377
What this trial is testing

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI) 3,680
Testing effectiveness (Phase 2)Looking for participantsNCT06726148
What this trial is testing

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsExtensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals 280
Early research (Phase 1)Ended earlyNCT01805908
What this trial is testing

Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)

Who this might be right for
Breast Cancer
Ontario Clinical Oncology Group (OCOG) 3
Very early researchLooking for participantsNCT04684459
What this trial is testing

Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors

Who this might be right for
Peritoneal Carcinoma MetastaticPleural Effusion, MalignantHER2 Positive Malignancies
Sichuan University 18
Early research (Phase 1)Study completedNCT03319459
What this trial is testing

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Who this might be right for
HER2 Positive Gastric CancerColorectal CancerHead and Neck Squamous Cell Carcinoma+8 more
Fate Therapeutics 44
Not applicableApproved For MarketingNCT04220203
What this trial is testing

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Early research (Phase 1)UnknownNCT04660929
What this trial is testing

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positiveAdenocarcinomaBile Duct Cancer+28 more
Carisma Therapeutics Inc 48
Not applicableStudy completedNCT00433407
What this trial is testing

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Who this might be right for
Breast CancerLung CancerOvarian Cancer+3 more
Jonsson Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT01548677
What this trial is testing

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

Who this might be right for
Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastCirculating Tumor Cells
European Organisation for Research and Treatment of Cancer - EORTC 1,317
Next Page